Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Case-Based Guide to Clinical EndocrinologyWhen and How to Stop Cabergoline Treatment in Microprolactinomas

A Case-Based Guide to Clinical Endocrinology: When and How to Stop Cabergoline Treatment in... Chapter 2 When and How to Stop Cabergoline Treatment in Microprolactinomas Annamaria Colao Prolactinomas are the most frequent pituitary tumors with an estimated prevalence in the adult population of 100 per million population [1]. Their frequency varies with age and sex, occurring most frequently in women between 20 and 50 years of age; in the pediatric/adolescent age group, prolactinomas are rare, but represent about half of all pituitary adenomas [1]. Prolactin (PRL) excess causes gonadal and sexual dysfunction, while other symptoms related to the tumor expansion may occur in patients with large macro- prolactinomas. In the presence of clear-cut symptoms of hyperprolactinemia and after excluding pregnancy or the use of drugs known to induce increase of PRL levels [1], the diagnosis is made by serial PRL measurements and by magnetic resonance imaging (MRI) of the sella before and after contrast enhancement. Elevated (generally mildly) PRL levels in the absence of symptoms may be due to macroprolactinemia, while modestly elevated PRL levels in a patient with a large tumor may be expres- sion of a pseudoprolactinoma (pituitary stalk section in a clinically nonfunctioning macroadenoma) [1]. However, in this latter case if PRL levels were measured by immunoradiometric assay (IRMA), the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

A Case-Based Guide to Clinical EndocrinologyWhen and How to Stop Cabergoline Treatment in Microprolactinomas

Part of the Contemporary Endocrinology™ Book Series
Editors: Davies, Terry F.
Colao, Annamaria
A Case-Based Guide to Clinical Endocrinology — Jan 1, 2008
Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/a-case-based-guide-to-clinical-endocrinology-when-and-how-to-stop-7oTiMrSpRs
Publisher
Humana Press
Copyright
© Humana Press,Totowa, NJ 2008
ISBN
978-1-58829-815-7
Pages
19 –25
DOI
10.1007/978-1-60327-103-5_2
Publisher site
See Chapter on Publisher Site

Abstract

Chapter 2 When and How to Stop Cabergoline Treatment in Microprolactinomas Annamaria Colao Prolactinomas are the most frequent pituitary tumors with an estimated prevalence in the adult population of 100 per million population [1]. Their frequency varies with age and sex, occurring most frequently in women between 20 and 50 years of age; in the pediatric/adolescent age group, prolactinomas are rare, but represent about half of all pituitary adenomas [1]. Prolactin (PRL) excess causes gonadal and sexual dysfunction, while other symptoms related to the tumor expansion may occur in patients with large macro- prolactinomas. In the presence of clear-cut symptoms of hyperprolactinemia and after excluding pregnancy or the use of drugs known to induce increase of PRL levels [1], the diagnosis is made by serial PRL measurements and by magnetic resonance imaging (MRI) of the sella before and after contrast enhancement. Elevated (generally mildly) PRL levels in the absence of symptoms may be due to macroprolactinemia, while modestly elevated PRL levels in a patient with a large tumor may be expres- sion of a pseudoprolactinoma (pituitary stalk section in a clinically nonfunctioning macroadenoma) [1]. However, in this latter case if PRL levels were measured by immunoradiometric assay (IRMA), the

Published: Jan 1, 2008

Keywords: Pituitary Adenoma; Dopamine Agonist; Positive Magnetic Resonance Imaging; Cabergoline Treatment; Dopamine Agonist Treatment

There are no references for this article.